These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24410307)

  • 21. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular toxicity of fluoroquinolones.
    Thompson AM
    Clin Exp Ophthalmol; 2007 Aug; 35(6):566-77. PubMed ID: 17760640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety profile of the fluoroquinolones.
    Bertino J; Fish D
    Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term toxicity of fluoroquinolones: a comprehensive review.
    Hussen NHA; Qadir SH; Rahman HS; Hamalaw YY; Kareem PSS; Hamza BA
    Drug Chem Toxicol; 2024 Sep; 47(5):795-806. PubMed ID: 37501614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of side effects of levofloxacin versus other fluoroquinolones.
    Carbon C
    Chemotherapy; 2001; 47 Suppl 3():9-14; discussion 44-8. PubMed ID: 11549784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of an in vitro cellular phototoxicity model against controlled clinical trials of fluoroquinolone skin phototoxicity.
    Traynor NJ; Barratt MD; Lovell WW; Ferguson J; Gibbs NK
    Toxicol In Vitro; 2000 Jun; 14(3):275-83. PubMed ID: 10806378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolones: old drugs, putative new toxicities.
    Bove C; Baldock RA; Champigneulle O; Martin L; Bennett CL
    Expert Opin Drug Saf; 2022 Nov; 21(11):1365-1378. PubMed ID: 36384376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone-associated tendinopathy.
    Tsai WC; Yang YM
    Chang Gung Med J; 2011; 34(5):461-7. PubMed ID: 22035890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability of fluoroquinolone antibiotics. Past, present and future.
    Ball P; Tillotson G
    Drug Saf; 1995 Dec; 13(6):343-58. PubMed ID: 8652079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone-induced tendinopathy: etiology and preventive measures.
    Kaleagasioglu F; Olcay E
    Tohoku J Exp Med; 2012 Apr; 226(4):251-8. PubMed ID: 22452935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin.
    Dawe RS; Ferguson J; Ibbotson S; Lawrence L; Paulson S; Duffy E; Cammarata S
    Photochem Photobiol Sci; 2018 Jun; 17(6):773-780. PubMed ID: 29721574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety.
    Rodvold KA; Piscitelli SC
    Clin Infect Dis; 1993 Aug; 17 Suppl 1():S192-9. PubMed ID: 8399914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolones in the elderly: safety considerations.
    Stahlmann R; Lode H
    Drugs Aging; 2003; 20(4):289-302. PubMed ID: 12641485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.
    Mehrzad R; Barza M
    J Clin Pharmacol; 2015 Nov; 55(11):1198-206. PubMed ID: 26011799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.
    Golomb BA; Koslik HJ; Redd AJ
    BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26438672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones].
    Hayashi N
    Yakugaku Zasshi; 2005 Mar; 125(3):255-61. PubMed ID: 15738624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical review of delafloxacin: a novel anionic fluoroquinolone.
    Mogle BT; Steele JM; Thomas SJ; Bohan KH; Kufel WD
    J Antimicrob Chemother; 2018 Jun; 73(6):1439-1451. PubMed ID: 29425340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysglycaemias and fluoroquinolones.
    Lewis RJ; Mohr JF
    Drug Saf; 2008; 31(4):283-92. PubMed ID: 18366239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.